All In Biotech

Drug Trial Radar · NCT06899217

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Jan 29, 2025

Primary completion

May 7, 2026

Study completion May 7, 2026

Sponsor

Lead sponsor
CinDome Pharma, Inc.Industry
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Participants will go through the following schedule: * Pre-screening (1 visit) * Screening \& Lead-In (1-2 visits) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation. * Lead-In Period (1 visit) * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * 15 mg CIN-102, taken orally BID for 12 weeks * 10 mg CIN-102, taken orally BID for 12 weeks * Placebo for CIN-102, taken orally BID for 12 weeks

Conditions

  • Idiopathic Gastroparesis

Interventions

  • CIN-102 Dose 15mgDrug

    Twice daily for 12 weeks

  • PlaceboDrug

    Twice daily for 12 weeks

  • CIN-102 Dose 10mgDrug

    Twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline

Locations

85 sites in 1 country. Site status is shown where the registry gives one.

  • Gastro Health - Birmingham

    Birmingham, Alabama

  • G & L Research, LLC

    Foley, Alabama

  • The Center for Clinical Trials

    Saraland, Alabama

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • Applied Research Center of Arkansas, Inc

    Little Rock, Arkansas

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Hope Clinical Research LLC

    Canoga Park, California

  • Erick H. Alayo Medical Corporation

    Chula Vista, California

  • Flourish Research - Los Angeles (Covina)

    Covina, California

  • Gastro Care Institute

    Lancaster, California

  • Downtown L.A. Research Center, Inc.

    Los Angeles, California

  • Acclaim Clinical Research

    San Diego, California

  • Focus Clinical Research - West Hills

    West Hills, California

  • University of Colorado Anschutz

    Aurora, Colorado

  • Rocky Mountain Gastroenterology (RMG)

    Lakewood, Colorado

  • Paradigm Research - Wheatridge

    Wheat Ridge, Colorado

  • Connecticut Clinical Research Institute, LLC

    Bristol, Connecticut

  • American Family Research Group

    Cape Coral, Florida

  • USA and International Research Inc.

    Doral, Florida

  • Unique Clinical Trials

    Doral, Florida

  • Advanced Medical Research Group

    Hollywood, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • ENCORE Borland Groover Clinical Research

    Jacksonville, Florida

  • Allied Biomedical Research Institute, Inc.

    Miami, Florida

  • Advanced Research Institute Inc

    New Port Richey, Florida

  • Sensible Healthcare, LLC

    Ocoee, Florida

  • GCP Research

    St. Petersburg, Florida

  • Summit Clinical Research, LLC

    Athens, Georgia

  • DelRicht Clinical Research - Atlanta

    Atlanta, Georgia

  • Gastrointestinal Specialists of Georgia PC

    Marietta, Georgia

  • Treasure Valley Medical Research

    Boise, Idaho

  • GI Alliance - Gurnee

    Gurnee, Illinois

  • Carle Clinic - Urbana Main

    Urbana, Illinois

  • Integrated Clinical Trial Services, Inc

    West Des Moines, Iowa

  • Kansas Medical Clinic, P.A.

    Topeka, Kansas

  • University of Louisville

    Louisville, Kentucky

  • Tandem Clinical Research

    Marrero, Louisiana

  • Delta Research Partners of West Monroe, LLC

    Monroe, Louisiana

  • NOLA Research Works

    New Orleans, Louisiana

  • Portland Gastroenterology Associates

    Portland, Maine

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.